Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 6 | 2025 | 456 | 1.420 |
Why?
|
| Nicotine | 1 | 2025 | 113 | 0.880 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2025 | 71 | 0.870 |
Why?
|
| Delay Discounting | 1 | 2020 | 3 | 0.720 |
Why?
|
| Intimate Partner Violence | 2 | 2017 | 25 | 0.680 |
Why?
|
| Smoking Cessation | 1 | 2025 | 541 | 0.650 |
Why?
|
| Drug Overdose | 2 | 2020 | 126 | 0.650 |
Why?
|
| Anxiety | 3 | 2017 | 387 | 0.600 |
Why?
|
| Motivation | 1 | 2020 | 274 | 0.590 |
Why?
|
| Crime Victims | 2 | 2017 | 32 | 0.580 |
Why?
|
| Sex Offenses | 2 | 2017 | 46 | 0.580 |
Why?
|
| Self-Control | 1 | 2017 | 5 | 0.580 |
Why?
|
| Stalking | 1 | 2017 | 2 | 0.570 |
Why?
|
| Depressive Disorder, Major | 7 | 2012 | 246 | 0.520 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 259 | 0.520 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 186 | 0.500 |
Why?
|
| Emotions | 1 | 2017 | 214 | 0.480 |
Why?
|
| Veterans | 5 | 2025 | 728 | 0.470 |
Why?
|
| Opiate Substitution Treatment | 3 | 2022 | 187 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 381 | 0.350 |
Why?
|
| Antidepressive Agents | 5 | 2011 | 212 | 0.340 |
Why?
|
| Alcoholism | 2 | 2025 | 309 | 0.330 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 483 | 0.300 |
Why?
|
| Patient Discharge | 2 | 2022 | 490 | 0.290 |
Why?
|
| Humans | 24 | 2025 | 59387 | 0.240 |
Why?
|
| Students | 2 | 2017 | 202 | 0.240 |
Why?
|
| Harm Reduction | 1 | 2025 | 29 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 677 | 0.230 |
Why?
|
| Suicide | 1 | 2025 | 119 | 0.210 |
Why?
|
| Chronic Pain | 1 | 2024 | 134 | 0.200 |
Why?
|
| Aftercare | 1 | 2022 | 69 | 0.190 |
Why?
|
| Acupuncture Therapy | 2 | 2012 | 13 | 0.190 |
Why?
|
| Buprenorphine | 2 | 2021 | 181 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2022 | 5284 | 0.180 |
Why?
|
| Residential Treatment | 1 | 2020 | 30 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 706 | 0.170 |
Why?
|
| Quality of Life | 2 | 2025 | 1137 | 0.170 |
Why?
|
| Self Efficacy | 1 | 2020 | 194 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 119 | 0.160 |
Why?
|
| Violence | 2 | 2017 | 148 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 177 | 0.160 |
Why?
|
| Rumination, Cognitive | 1 | 2017 | 1 | 0.150 |
Why?
|
| Behavioral Sciences | 1 | 2017 | 2 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2017 | 23 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2025 | 686 | 0.140 |
Why?
|
| Psychological Trauma | 1 | 2017 | 20 | 0.140 |
Why?
|
| Adult | 9 | 2025 | 15687 | 0.140 |
Why?
|
| Rape | 1 | 2016 | 15 | 0.130 |
Why?
|
| Social Perception | 1 | 2016 | 38 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 379 | 0.130 |
Why?
|
| Sexual and Gender Minorities | 1 | 2016 | 70 | 0.120 |
Why?
|
| Middle Aged | 6 | 2025 | 16320 | 0.110 |
Why?
|
| Fluoxetine | 2 | 2011 | 44 | 0.110 |
Why?
|
| Male | 12 | 2025 | 27751 | 0.100 |
Why?
|
| Sex Factors | 2 | 2025 | 935 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 113 | 0.090 |
Why?
|
| Hypericum | 1 | 2011 | 3 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Female | 12 | 2025 | 30728 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 52 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 138 | 0.090 |
Why?
|
| Clonazepam | 1 | 2010 | 3 | 0.080 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 121 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 104 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2012 | 715 | 0.080 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2008 | 10 | 0.080 |
Why?
|
| Sound | 1 | 2008 | 11 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2013 | 442 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 288 | 0.070 |
Why?
|
| Speech Perception | 1 | 2008 | 79 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1252 | 0.070 |
Why?
|
| Animals | 1 | 2025 | 19651 | 0.070 |
Why?
|
| Depression | 1 | 2013 | 829 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 710 | 0.060 |
Why?
|
| Comorbidity | 2 | 2024 | 1078 | 0.060 |
Why?
|
| Age Factors | 2 | 2025 | 1504 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2025 | 34 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 635 | 0.060 |
Why?
|
| Cause of Death | 1 | 2025 | 210 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 788 | 0.050 |
Why?
|
| Time Factors | 4 | 2012 | 3615 | 0.050 |
Why?
|
| Young Adult | 4 | 2016 | 4272 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 197 | 0.050 |
Why?
|
| Demography | 2 | 2013 | 169 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 25 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 67 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2025 | 519 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 111 | 0.040 |
Why?
|
| Narcotics | 1 | 2020 | 50 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 77 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 486 | 0.040 |
Why?
|
| Risk Factors | 2 | 2025 | 4986 | 0.040 |
Why?
|
| United States | 2 | 2025 | 7425 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 603 | 0.040 |
Why?
|
| Arousal | 1 | 2020 | 41 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2020 | 53 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2020 | 56 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 127 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 2378 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 914 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 13415 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 306 | 0.040 |
Why?
|
| Internet | 1 | 2020 | 448 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 148 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 73 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 616 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 288 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 5835 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3067 | 0.030 |
Why?
|
| Psychology, Comparative | 1 | 2013 | 1 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 58 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1479 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 61 | 0.020 |
Why?
|
| Acupuncture Points | 1 | 2012 | 5 | 0.020 |
Why?
|
| Sertraline | 1 | 2011 | 58 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 211 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 137 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 68 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 742 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 137 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 333 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 185 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 31 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 354 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6072 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 20 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 50 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 452 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 134 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 555 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1234 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2008 | 228 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2379 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1925 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2340 | 0.020 |
Why?
|